BioCryst Pharmaceuticals (BCRX) Undervalued Narrative Gains Traction: Is BCRX Undervalued?

BioCryst Pharmaceuticals (BCRX) has recently gained investor attention with its shares closing at $7.92. The company has experienced mixed return patterns over the past year, with ongoing revenue and net income growth. Analysts have revised their price target to $20.60, citing the planned $700m acquisition of Astria Therapeutics and the potential of HAE candidate navenibart. The narrative indicates that BioCryst is undervalued, but this hinges on ORLADEYO's resilience in a crowded HAE market and navenibart clearing clinical and regulatory hurdles.